Stephen Gunstream
CEO & President Teknova
Stephen Gunstream has served as Teknova’s President and Chief Executive Officer since May 2020, after initially joining the company in 2019 as Chief Business Officer. He brings over 20 years of experience in sales, marketing, R&D, and general management within the life sciences industry. Before Teknova, he held several leadership positions at BD, most recently serving as Vice President and General Manager of BD Biosciences, where he led the flow cytometry and genomics business. Prior to BD, he spent seven years at Integrated DNA Technologies (IDT), ultimately becoming Chief Commercial Officer and helping launch innovative products such as the xGen® Exome Panel and gBlocks® Gene Fragments, for which he is a co‑inventor. He also held product and business development roles at Applied Biosystems earlier in his career. Stephen holds a bachelor’s degree in biomedical engineering from Northwestern University and an MBA from Duke University, and he is named on 10 issued and more than 25 pending patents.
Seminars
- Novel therapeutic development is focused on increasingly individualized solutions, requiring smaller, more customized batches of reagents and buffers to be used across the clinical pipeline as companies scale from research to process development and into commercialization.
- Existing bioprocessing infrastructure was not designed to manufacture these next-generation therapies, forcing the industry to look for research-and-clinical-grade reagent formulations that are easily customizable, scalable, and efficiently manufactured.
- Teknova has been able to leverage their modular manufacturing platform to help novel therapy developers across cell and gene therapy, mRNA, and next-generation antibodies (ADCs and multispecifics) accelerate their breakthroughs to get into the clinical faster.
- Find out more about what criteria novel therapy developers should be considering when evaluating reagent solutions.
